ESE Election results

Programme for the Study of Metabolic Toxicity in Diabetes

Novartis says Aclasta better at boosting bone mass (Reuters, 11 April 2008)

21 Apr 2008

Novartis's drug Aclasta has shown greater promise in increasing bone mass in osteoporosis patients than Procter & Gamble Co's drug, Actonel.

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read